241 related articles for article (PubMed ID: 14688082)
1. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
Li X; Lockatell CV; Johnson DE; Lane MC; Warren JW; Mobley HL
Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
[TBL] [Abstract][Full Text] [Related]
3. Vaccination to Protect Against Proteus mirabilis Challenge Utilizing the Ascending Model of Urinary Tract Infection.
Smith SN; Himpsl SD; Mobley HLT
Methods Mol Biol; 2019; 2021():201-215. PubMed ID: 31309507
[TBL] [Abstract][Full Text] [Related]
4. Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.
Li X; Erbe JL; Lockatell CV; Johnson DE; Jobling MG; Holmes RK; Mobley HL
Infect Immun; 2004 Dec; 72(12):7306-10. PubMed ID: 15557656
[TBL] [Abstract][Full Text] [Related]
5. Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis.
Li X; Johnson DE; Mobley HL
Infect Immun; 1999 Jun; 67(6):2822-33. PubMed ID: 10338487
[TBL] [Abstract][Full Text] [Related]
6. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
[TBL] [Abstract][Full Text] [Related]
7. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
[TBL] [Abstract][Full Text] [Related]
8. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
9. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
Scavone P; Sosa V; Pellegrino R; Galvalisi U; Zunino P
Microbes Infect; 2004 Jul; 6(9):853-60. PubMed ID: 15374007
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
Habibi M; Asadi Karam MR; Bouzari S
Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
[TBL] [Abstract][Full Text] [Related]
11. Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract.
Scavone P; Umpiérrez A; Maskell DJ; Zunino P
J Med Microbiol; 2011 Jul; 60(Pt 7):899-904. PubMed ID: 21415205
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections.
Pellegrino R; Galvalisi U; Scavone P; Sosa V; Zunino P
FEMS Immunol Med Microbiol; 2003 May; 36(1-2):103-10. PubMed ID: 12727373
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice.
Scavone P; Miyoshi A; Rial A; Chabalgoity A; Langella P; Azevedo V; Zunino P
Microbes Infect; 2007 Jun; 9(7):821-8. PubMed ID: 17540603
[TBL] [Abstract][Full Text] [Related]
14. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P
Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
[TBL] [Abstract][Full Text] [Related]
15. Vaccines for Proteus mirabilis in urinary tract infection.
Li X; Mobley HL
Int J Antimicrob Agents; 2002 Jun; 19(6):461-5. PubMed ID: 12135833
[TBL] [Abstract][Full Text] [Related]
16. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL
Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
[TBL] [Abstract][Full Text] [Related]
18. Fimbriae of uropathogenic Proteus mirabilis.
Rocha SP; Pelayo JS; Elias WP
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):1-7. PubMed ID: 17640292
[TBL] [Abstract][Full Text] [Related]
19. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract.
Scavone P; Rial A; Umpierrez A; Chabalgoity A; Zunino P
Microbiol Immunol; 2009 Apr; 53(4):233-40. PubMed ID: 19714860
[TBL] [Abstract][Full Text] [Related]
20. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract.
Zhao H; Li X; Johnson DE; Blomfield I; Mobley HL
Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
